Skip to main content

Table 2 Investigations and data acquisition during the trial

From: Effect of Pycnogenol® on attention-deficit hyperactivity disorder (ADHD): study protocol for a randomised controlled trial

 

Screening

Baseline

  

Evaluations/interventions

Week 0

Week 0

Week 5

Week 10

Inclusion and exclusion criteria

X

X

  

Current use of medication/supplements

X

X

X

X

Informed consents

 

X

  

Randomisation

 

X

  

Treatment

    

Treatment distribution

 

X

  

Medication count

 

X

 

X

ADHD-RS

 

X

X

X

SEQ

 

X

 

X

PCQ

 

X

X

X

FFQ

 

X

 

X

Blood and urine collection

 

X

 

X

Faeces collection

 

X

 

X

GSH analysis

 

X

 

X

Lipid-soluble antioxidants analysis

 

X

 

X

Antioxidant enzyme activity

 

X

 

X

Genetics analysis

 

X

 

X

MDA analysis

 

X

 

X

8-OHdG analysis

 

X

 

X

Cytokine analysis

 

X

 

X

Antibody analysis

 

X

 

X

PBMC count and reactivity analysis

 

X

 

X

Microbial composition analysis

 

X

 

X

Catecholamine analysis

 

X

 

X

NPY analysis

 

X

 

X

Zinc analysis

 

X

 

X

  1. 8-OHdG 8-hydroxy-2-deoxyguanosine, ADHD-RS ADHD-Rating Scale, FFQ Food Frequency Questionnaire, GSH erythrocyte glutathione, MDA plasma malondialdehyde, NPY serum neuropeptide Y, PBMC peripheral blood mononuclear cell, PCQ Physical Complaints Questionnaire, SEQ Social-Emotional Questionnaire